Search

Your search keyword '"Sharma, Ashish"' showing total 110 results
Start Over Author "Sharma, Ashish" Journal eye
110 results on '"Sharma, Ashish"'

1. The Port Delivery System with ranibizumab—journey of mitigating vitreous hemorrhage

Author

Sharma, Ashish, Parachuri, Nikulaa, Kumar, Nilesh, Kuppermann, Baruch D, and Bandello, Francesco

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Angiogenesis Inhibitors, Humans, Intravitreal Injections, Ranibizumab, Vitreous Hemorrhage, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2022

2. Semaglutide and the risk of diabetic retinopathy—current perspective

Author

Sharma, Ashish, Parachuri, Nikulaa, Kumar, Nilesh, Saboo, Bharat, Tripathi, Hridaya Nath, Kuppermann, Baruch D, and Bandello, Francesco

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2022

3. Brolucizumab—foreseeable workflow in the current scenario

Author

Sharma, Ashish, Kumar, Nilesh, Parachuri, Nikulaa, Kuppermann, Baruch D, Bandello, Francesco, Regillo, Carl D, Boyer, David, and Nguyen, Quan Dong

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Antibodies, Monoclonal, Humanized, Humans, Receptors, Vascular Endothelial Growth Factor, Workflow, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2021

4. Vortex vein anastomosis and pachychoroid—an evolving understanding

Author

Sharma, Ashish, Parachuri, Nikulaa, Kumar, Nilesh, Bandello, Francesco, Kuppermann, Baruch D, Loewenstein, Anat, Regillo, Carl D, and Chakravarthy, Usha

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Anastomosis, Surgical, Choroid, Fluorescein Angiography, Humans, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2021

6. Comment on: ‘Recent advances in anterior chamber angle imaging’

Author

Kumar, Nilesh, Bandello, Francesco, Kuppermann, Baruch D, and Sharma, Ashish

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Anterior Chamber, Glaucoma, Angle-Closure, Humans, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2020

7. Brolucizumab and immunogenicity

Author

Sharma, Ashish, Kumar, Nilesh, Parachuri, Nikulaa, Sharma, Rohini, Bandello, Francesco, Kuppermann, Baruch D, and Loewenstein, Anat

Subjects
Antibodies, Monoclonal, Humanized, Humans, Intravitreal Injections, Clinical Sciences, Immunology, Opthalmology and Optometry, Ophthalmology & Optometry
Published
2020

8. Brolucizumab—another anti-VEGF or beyond

Author

Sharma, Ashish, Parachuri, Nikulaa, Kumar, Nilesh, Sharma, Rohini, Bandello, Francesco, Kuppermann, Baruch D, and Loewenstein, Anat

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Humans, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2020

9. Pachydrusen: the epidemiology of pachydrusen and its relevance to progression of pachychoroid disease spectrum

Author

Sheth, Jay, Anantharaman, Giridhar, Kumar, Nilesh, Parachuri, Nikulaa, Bandello, Francesco, Kuppermann, Baruch D, Loewenstein, Anat, and Sharma, Ashish

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Choroid, Fluorescein Angiography, Humans, Tomography, Optical Coherence, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2020

10. Smartphone based ROP (S-ROP) screening—opportunities and challenges

Author

patil, Jayaprakash, patil, Laxmi, Parachuri, Nikulaa, Kumar, Nilesh, Bandello, Francesco, Kuppermann, Baruch D, Loewenstein, Anat, and Sharma, Ashish

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Birth Weight, Gestational Age, Humans, Infant, Newborn, Mass Screening, Neonatal Screening, Retinopathy of Prematurity, Smartphone, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2020

11. Brolucizumab-key learnings from HAWK and HARRIER

Author

Sharma, Ashish, Parachuri, Nikulaa, Kumar, Nilesh, Sharma, Rohini, Bandello, Francesco, Kuppermann, Baruch D, and Loewenstein, Anat

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Animals, Antibodies, Monoclonal, Humanized, Hawks, Humans, Intravitreal Injections, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2020

12. Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)

Author

Sharma, Ashish, Kumar, Nilesh, Parachuri, Nikulaa, Sharma, Rohini, Bandello, Francesco, Kuppermann, Baruch D, and Regillo, Carl D

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Antibodies, Monoclonal, Humanized, Choroidal Neovascularization, Humans, Macular Degeneration, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2020

13. Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations-GEODEX-IOP study.

Author

Bandello, Francesco, Lanzetta, Paolo, Zur, Dinah, Park, Sung, Yu, Hyeong, Saravanan, V, Zacharias, Leandro, Barreira, Alan, Iglicki, Matias, Miassi, Fernando, Veritti, Daniele, Tsao, Sean, Makam, Deepika, Jain, Nidhee, Loewenstein, Anat, Sharma, Ashish, and Kuppermann, Baruch

Subjects
Dexamethasone, Diabetic Retinopathy, Drug Implants, Glucocorticoids, Humans, India, Intraocular Pressure, Intravitreal Injections, Israel, Macular Edema, Retinal Vein Occlusion, Retrospective Studies, Tomography, Optical Coherence
Abstract

PURPOSE: To analyse the intraocular pressure rise after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations. METHODS: The medical charts of 294 dexamethasone implants between February 2011 and 2017 were reviewed retrospectively. South Asian (India), White (Europe, US and Israel) Latino (Argentina and Brazil) patient data was included in the study. Ocular hypertension (OHT) was defined as intraocular pressure of >25 mmHg or an increase of at least 10 mmHg from baseline. The main indications for treatment were diabetic macular edema (ME) (65.6%), retinal vein occlusion (26.5%), uveitis (7.8%). RESULTS: Amongst 294 intravitreal implants, ocular hypertension (>25 mmHg) was recorded in 0, 8 and 9.5% in White, Latino, and South Asian groups, respectively. However, IOP > 20 mmHg was recorded in 14%, 28% and 27% in White, Latino, and South Asian groups, respectively. Incidence of very high IOP (>35 mmHg) was lower in all geographical groups. It was 3% in Latino followed by 2% in South Asian group. CONCLUSION: Latino and South Asian groups have higher IOP rise compared to White population. Most patients with elevated IOP fluctuate between 20-25 mmHg.

Published
2020

14. Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations—GEODEX-IOP study

Author

Sharma, Ashish, Kuppermann, Baruch D, Bandello, Francesco, Lanzetta, Paolo, Zur, Dinah, Park, Sung Wook, Yu, Hyeong Gon, Saravanan, VR, Zacharias, Leandro Cabral, Barreira, Alan K, Iglicki, Matias, Miassi, Fernando, Veritti, Daniele, Tsao, Sean, Makam, Deepika, Jain, Nidhee, and Loewenstein, Anat

Subjects
Biomedical and Clinical Sciences, Ophthalmology and Optometry, Clinical Trials and Supportive Activities, Clinical Research, Eye Disease and Disorders of Vision, Cardiovascular, Eye, Dexamethasone, Diabetic Retinopathy, Drug Implants, Glucocorticoids, Humans, India, Intraocular Pressure, Intravitreal Injections, Israel, Macular Edema, Retinal Vein Occlusion, Retrospective Studies, Tomography, Optical Coherence, Clinical Sciences, Immunology, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Abstract

PurposeTo analyse the intraocular pressure rise after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations.MethodsThe medical charts of 294 dexamethasone implants between February 2011 and 2017 were reviewed retrospectively. South Asian (India), White (Europe, US and Israel) Latino (Argentina and Brazil) patient data was included in the study. Ocular hypertension (OHT) was defined as intraocular pressure of >25 mmHg or an increase of at least 10 mmHg from baseline. The main indications for treatment were diabetic macular edema (ME) (65.6%), retinal vein occlusion (26.5%), uveitis (7.8%).ResultsAmongst 294 intravitreal implants, ocular hypertension (>25 mmHg) was recorded in 0, 8 and 9.5% in White, Latino, and South Asian groups, respectively. However, IOP > 20 mmHg was recorded in 14%, 28% and 27% in White, Latino, and South Asian groups, respectively. Incidence of very high IOP (>35 mmHg) was lower in all geographical groups. It was 3% in Latino followed by 2% in South Asian group.ConclusionLatino and South Asian groups have higher IOP rise compared to White population. Most patients with elevated IOP fluctuate between 20-25 mmHg.

Published
2020

15. Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect

Author

Sharma, Ashish, Kumar, Nilesh, Bandello, Francesco, Loewenstein, Anat, and Kuppermann, Baruch D

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Biosimilar Pharmaceuticals, Educational Status, Humans, Nocebo Effect, Ophthalmologists, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2020

16. Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data

Author

Sharma, Ashish, Hafeez Faridi, M, Kumar, Nilesh, Parachuri, Nikulaa, Sharma, Rohini, Kuppermann, Baruch D, Bandello, Francesco, Loewenstein, Anat, and Regillo, Carl D

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Biosimilar Pharmaceuticals, Drug Substitution, Humans, Infliximab, Ranibizumab, Treatment Outcome, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2020

17. Faricimab: expanding horizon beyond VEGF

Author

Sharma, Ashish, Kumar, Nilesh, Kuppermann, Baruch D, Bandello, Francesco, and Loewenstein, Anat

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Angiogenesis Inhibitors, Humans, Ranibizumab, Vascular Endothelial Growth Factor A, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2020

18. Abicipar pegol: the non-monoclonal antibody anti-VEGF

Author

Sharma, Ashish, Kumar, Nilesh, Kuppermann, Baruch D, and Bandello, Francesco

Subjects
Choroidal Neovascularization, Humans, Recombinant Fusion Proteins, Clinical Sciences, Immunology, Opthalmology and Optometry, Ophthalmology & Optometry
Published
2020

19. Ophthalmic biosimilars and biologics—role of endotoxins

Author

Sharma, Ashish, Kumar, Nilesh, Kuppermann, Baruch D, Bandello, Francesco, and Loewenstein, Anat

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Biosimilar Pharmaceuticals, Endotoxins, Humans, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2020

20. Brolucizimab—leading an era of structural revolution for long-term VEGF suppression

Author

Sharma, Ashish, Kumar, Nilesh, Kuppermann, Baruch D, and Bandello, Francesco

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Humans, Intravitreal Injections, Vascular Endothelial Growth Factor A, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2020

21. Brolucizumab: is extended VEGF suppression on the horizon?

Author

Sharma, Ashish, Kumar, Nilesh, Kuppermann, Baruch D, Loewenstein, Anat, and Bandello, Francesco

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Humans, Vascular Endothelial Growth Factor A, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2020

22. Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression

Author

Sharma, Ashish, Kumar, Nilesh, Parachuri, Nikulaa, Kuppermann, Baruch D, Bandello, Francesco, and Regillo, Carl D

Subjects
Ophthalmology and Optometry, Biomedical and Clinical Sciences, Immunology, Angiogenesis Inhibitors, Bevacizumab, Humans, Intravitreal Injections, Ranibizumab, Vascular Endothelial Growth Factor A, Clinical Sciences, Opthalmology and Optometry, Ophthalmology & Optometry, Ophthalmology and optometry
Published
2020

24. Role of retinal image-based counseling in the treatment of peripheral retinal lesions

Author

Sharma, Ashish, Dongre, Pankaj, Bellala, Keerthi, Reddy, Prahlad, Kuppermann, Baruch D, and Bandello, Francesco

Subjects
Counseling, Diagnostic Techniques, Ophthalmological, Disease Management, Humans, Retina, Retinal Diseases, Clinical Sciences, Immunology, Opthalmology and Optometry, Ophthalmology & Optometry
Published
2019

28. Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI)

Author

Sharma, Ashish, Kaiser, Peter K., Tadayoni, Ramin, Holz, Frank G., Nicholson, Luke, Vazquez-Alfageme, Clara, Sivaprasad, Sobha, Wakabayashi, Taku, Woo, Se Joon, Sarraf, David, Kumar, Nilesh, Parachuri, Nikulaa, Regillo, Carl D., Rezaei, Kourous A., Khanani, Arshad M., Bandello, Francesco, Shanamugam, Mahesh, Verma, Lalit, Dogra, Mangat Ram, NS, Muralidhar, Agarwal, Manisha, Loewenstein, Anat, and Kuppermann, Baruch D.

Published
2024
Full Text
View/download PDF

29. Subfoveal neurosensory detachment flattening and observe (SNF-Ob) approach for the management of Ci-DMO - a multicentric study

Author

Sharma, Ashish, Wakabayashi, Taku, Regillo, Carl D., Cheung, Chui Ming Gemmy, Loewenstein, Anat, Zur, Dinah, Goldberg, Dafna, Hilely, Assaf, Ozdek, Sengul, Özdemir, Hüseyin Baran, Parachuri, Nikulaa, Kumar, Nilesh, Kuppermann, Baruch D., Bandello, Francesco, and Querques, Giuseppe

Abstract

Purpose: To understand subfoveal neurosensory detachment flattening and observe (SNF-Ob) strategy and its relationship with visual acuity in the management of centre-involved diabetic macular oedema (Ci-DMO). Methods: This was a multicentric retrospective observational study. We reviewed data of 188 eyes of 130 patients who presented with Ci-DMO with subfoveal neurosensory detachment (NSD) and treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents or steroids. The primary outcome was best corrected visual acuity (BCVA) measured at the time of the first subfoveal neurosensory detachment flattening (SNF) and at the end of follow-up. Results: Eyes that achieved 20/50 (LogMAR = 0.40) or better at first SNF had mean LogMAR BCVA 0.38 ± 0.21, 0.24 ± 0.11 and 0.21 ± 0.15 at baseline, at the time of first SNF, and at the end of the last follow-up respectively. Mean LogMAR BCVA significantly improved from baseline to first SNF (p< 0.0001; 95% CI 0.115–0.183) and at the end of the last follow-up (p< 0.0001; 95% CI 0.126–0.213) with a change of Early Treatment Diabetic Retinopathy Study (ETDRS) 10 letters. There was no significant difference in improvement in BCVA from the first SNF and at the end of the last follow-up (p= 0.0781; 95% CI −0.002 to 0.046). Conclusions: Eyes presenting with Ci-DMO and subfoveal NSD are unlikely to improve at SNF with BCVA > 20/50 (LogMAR = 0.40). Further evidence is needed before the combination of good BCVA and SNF may be considered as endpoint of pharmacological therapy for DMO.

Published
2024
Full Text
View/download PDF

31. Approved biosimilar ranibizumab—a global update

Author

Sharma, Ashish, primary, Kondo, Mineo, additional, Iwahashi, Chiharu, additional, Parachuri, Nikulaa, additional, Kumar, Nilesh, additional, Bandello, Francesco, additional, Loewenstein, Anat, additional, and Kuppermann, Baruch D., additional

Published
2022
Full Text
View/download PDF

41. Correction: Brolucizumab—early real-world experience: BREW study

Author

Sharma, Ashish, primary, Kumar, Nilesh, additional, Parachuri, Nikulaa, additional, Sadda, Srinivas R., additional, Corradetti, Giulia, additional, Heier, Jeffrey, additional, Chin, Adam T., additional, Boyer, David, additional, Dayani, Pouya, additional, Arepalli, Sruthi, additional, and Kaiser, Peter, additional

Published
2020
Full Text
View/download PDF

45. Brolucizumab—early real-world experience: BREW study

Author

Sharma, Ashish, primary, Kumar, Nilesh, additional, Parachuri, Nikulaa, additional, Sadda, Srinivas R., additional, Corradetti, Giulia, additional, Heier, Jeffrey, additional, Chin, Adam T., additional, Boyer, David, additional, Dayani, Pouya, additional, Arepalli, Sruthi, additional, and Kaiser, Peter, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results